ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination trial with CR-001 on track to initiate in second half of 2026 Phase 1/2 trial of CR-003, an ITGB6-targeted ADC, ongoing in China CR-002, a PD-L1-targeted ADC, on track to enter the clinic in second half of 2026 Multiple key clinical data readouts anticipated beginning in Q1 2027 WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the first quarter ended March 31, 2026 and recent business highlights. “Crescent’s...

EXTON, Pa., April 29, 2026 (GLOBE NEWSWIRE) —    OMEGA FLEX, INC. (OFLX)         Three Months Ended March 31,             2026   2025         Net Sales   $ 23,093,000   $ 23,330,000                  Net Income attributable to Omega Flex, Inc.   $ 2,077,000   $ 3,568,000                  Earnings Per Share – Basic and Diluted   $ 0.21   $ 0.35                  Weighted Average Shares – Basic and Diluted     10,094,322     10,094,322         Dean W. Rivest, CEO, announced that net sales of Omega Flex, Inc. (the “Company”) for the first quarters of 2026 and 2025 were $23,093,000 and $23,330,000, respectively, decreasing $237,000 or 1.0%.  Net income for the first quarters of 2026 and 2025 were $2,007,000 and $3,568,000, respectively, decreasing $1,491,000 or 41.8%....

For the first quarter of 2026, the Company reports:Annualized return on average common equity (“ROACE”) of 17.0% and annualized operating ROACE of 17.7% Combined ratio of 89.8% Underwriting income of $187 million, an increase of $24 million, or 15%, compared to the first quarter of 2025 Book value per diluted common share of $78.19, an increase of $0.99, or 1.3%, compared to December 31, 2025PEMBROKE, Bermuda, April 29, 2026 (GLOBE NEWSWIRE) — AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or “the Company”) (NYSE: AXS) today announced financial results for the first quarter ended March 31, 2026. Commenting on the first quarter 2026 financial results, Vince Tizzio, President and CEO of AXIS Capital said: “AXIS began 2026 building on the profitable growth that has...

Performance HighlightsNet Income: Net income for the quarter ended March 31, 2026, was $2.5 million, or $0.23 per share, compared to $1.8 million, or $0.17 per share, recorded in the prior year quarter ended March 31, 2025. Cash Net Income: Cash net income for the quarter ended March 31, 2026, was $2.8 million, or $0.27 per share, compared to $2.1 million or $0.19 per share, recorded in the comparable 2025 quarter. Net Interest Margin and Spread: The Bank’s net interest margin increased 26 basis points to 3.52% during the quarter ended March 31, 2026, from 3.26% in the linked quarter ended December 31, 2025. The Bank’s net interest spread increased to 2.66% during the quarter ended March 31,2026, from 2.19% in the prior year quarter ended March 31, 2025. Non-Interest Income Growth: Due to an increase in loan sale volume and loan sale...

21Shares AG, the issuer of ETPs listed on various trading venues, has published its financialstatements for the financial year ending 31 December 2025. The financial statements are available at:https://www.21shares.com/en-ch/product-documents/financials Contact:Email: press@21shares.comPhone: +41 44 260 86 60 About 21Shares AG:21Shares AG, Pelikanstrasse 37, 8001 Zurich, is a Swiss corporation registered in the commercial register of Zurich under the number CHE-347.562.100. It was incorporated on 27 July 2018 and its purpose is the issuance of Exchange Traded Products (ETPs) in Switzerland and worldwide.

29 April 2026, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS 2025EPH European Property Holdings PLC (“EPH” or the “Company”) has continued to achieve stable operational growth in the 2025 financial year. Rental income increased by 3.4% compared to the last year, mainly supported by rent indexations and active asset management, which ensured near-full occupancy. As of 31 December 2025, EPH’s real estate portfolio comprised ten high-quality assets in prime locations across Germany, Austria and Switzerland, with a total value of EUR 821.49 million, reflecting the slightly positive valuation development during the year. The properties meet high sustainability standards, as evidenced by relevant certifications, and are leased to tenants with strong credit profiles emphasising the portfolio’s stability and...

Festi’s operations in line with expectations – Q1 profit amounted to ISK 218 million Main results in Q1 2026Sales of goods amounted to ISK 40,061 million, an increase of 6.0% YoY. Margin from sales of goods and services amounted to ISK 9,747 million, an increase of 5.8% YoY. Gross margin was 24.3%, decreasing by 0.1 p.p. from Q1 2025, but by 0.6 p.p. excluding the effects of exchange rates, changes in global fuel markets and changes in public levies on fuel at the turn of the year. EBITDA amounted to ISK 2,565 million, increasing by 3.0% YoY. Profit amounted to ISK 218 million and return on equity was 13.7%. Net cash from operating activities was negative by ISK 32 million, with one-off effects in operating-related assets and liabilities explaining the YoY difference. Interest-bearing debt was refinanced during the quarter for approximately...

Q1 revenue of €203.3 million, down -8.6%Stronger seasonality due to unfavorable weather conditions at the start of the year, especially in Germany, Poland, and for the Energy activities in FranceConnectivity in France (13% of group revenue): continuation of accelerated adaptation measuresRevenue down -29.9% in Q1 First structural actions launched at the end of 2025 completed under good execution conditions Continued reduction of exposure to least profitable activitiesSolid fundamentals across the rest of the GroupEnergy becomes Solutions30’s largest revenue contributor in France, in well-oriented markets Gradual resumption of fiber roll-out in Belgium Strong positioning with established telecom service providers in Germany, in a market undergoing structuring  Q1In millions of euros 2026 2025 restated* % changeGroup 203.3 222.3         -8.6%Benelux 81.6 88.7         -8.0%France 69.8 76.3         -8.6%Germany 19.0 21.9         -13.5%Other...

Clermont-Ferrand – April 29, 2026 COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Financial information for the three months ended March 31, 2026 Michelin delivered a solid performance in the first quarter, the decline in revenue reflecting changes in exchange rates. In a highly uncertain environment, the Group is adapting its steering and maintaining its 2026 guidance. Group revenue amounted to €6.2 billion for the quarter, down 5.4% on a reported basis but stable at constant exchange ratesCurrency effect accounted for the entire decline, reflecting euro’s strong appreciation against US dollar and most currencies. Tire sales reported a modest decline in volume (-1.4%), confirming the positive trend observed in the fourth quarter of 2025. Replacement sales increased, boosted by a strong performance from the MICHELIN brand (+3% in...

Enrolment completed in Phase 2 part of head and neck cancer clinical trial (TG4050) – Topline data expected by the end of Q1 2028 as per plan Phase 1 data from TG4050 in head and neck cancer published on medRxiv License agreement signed with NEC Bio to advance clinical development of TG4050 in head and neck cancer Financial visibility until early 2028Strasbourg, France, April 29, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update on its myvac® platform, and its individualized neoantigen therapeutic vaccine (INTV) TG4050, and upcoming plans, including its financial position as of March 31, 2026. TG4050, Transgene’s first INTV from its myvac® platform continues to progress according to plan in the adjuvant...